Association of FGF-2 Concentrations with Atheroma Progression in Chronic Kidney Disease Patients

Background and objectives: Atherosclerosis is highly prevalent in CKD. The rate of progression of atherosclerosis is associated with cardiovascular events. Fibroblast growth factor 2 (FGF-2) is a member of the FGF family with potentially both protective and deleterious effects in the development of...

Descripción completa

Detalles Bibliográficos
Autores: Bozic, Milica, Betriu i Bars, M. Àngels, Bermúdez López, Marcelino, Ortiz, Alberto, Fernández i Giráldez, Elvira, Valdivielso Revilla, José Manuel
Tipo de recurso: artículo
Estado:Versión aceptada para publicación
Fecha de publicación:2018
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:10459.1/63140
Acceso en línea:https://doi.org/10.2215/CJN.07980717
http://hdl.handle.net/10459.1/63140
Access Level:acceso abierto
Palabra clave:Atherosclerosis
Cardiovascular disease
Plaque, Atherosclerotic
id ES_8f2fb9a0c0d30bfbc786dd6e2ff5ecad
oai_identifier_str oai:recercat.cat:10459.1/63140
network_acronym_str ES
network_name_str España
repository_id_str
spelling Association of FGF-2 Concentrations with Atheroma Progression in Chronic Kidney Disease PatientsSubclinical Atheromatosis progression and FGF-2 in CKDBozic, MilicaBetriu i Bars, M. ÀngelsBermúdez López, MarcelinoOrtiz, AlbertoFernández i Giráldez, ElviraValdivielso Revilla, José ManuelAtherosclerosisCardiovascular diseasePlaque, AtheroscleroticBackground and objectives: Atherosclerosis is highly prevalent in CKD. The rate of progression of atherosclerosis is associated with cardiovascular events. Fibroblast growth factor 2 (FGF-2) is a member of the FGF family with potentially both protective and deleterious effects in the development of atherosclerosis. The role of circulating FGF-2 levels in the progression of atherosclerosis in CKD is unknown. Design, setting, participants, & measurements: We used a multicenter, prospective, observational cohorts study of 481 patients with CKD. We determined the presence of atheroma plaque in ten arterial territories by carotid and femoral ultrasounds. Progression of atheromatosis was defined as an increase in the number of territories with plaque after 24 months. Plasma levels of FGF-2 were measured by multiplex analysis. A multivariable logistic regression analysis was performed to determine whether plasma FGF-2 levels were associated with atheromatosis progression. Results: Average age of the population was 61 years. The percentage of patients in each CKD stage was 51% in stage 3, 41% in stages 4–5, and 8% in dialysis. A total of 335 patients (70%) showed plaque at baseline. Atheromatosis progressed in 289 patients (67%). FGF-2 levels were similar between patients with or without plaque at baseline (79 versus 88 pg/ml), but lower in patients with atheromatosis progression after 2 years (78 versus 98 pg/ml; P<0.01). In adjusted analyses, higher plasma FGF-2 was associated with lower risk of atheromatosis progression (odds ratio [OR], 0.86; 95% confidence interval [95% CI], 0.76 to 0.96; per 50 pg/ml increment). Analysis of FGF-2 in tertiles showed that atheroma progression was observed for 102 participants in the lowest tertile of FGF-2 (reference group), 86 participants in the middle tertile of FGF-2 (adjusted OR, 0.70; 95% CI, 0.40 to 1.20), and 74 participants in the lowest tertile of FGF-2 (adjusted OR, 0.48; 95% CI, 0.28 to 0.82). Conclusions: Low FGF-2 levels are independently associated with atheromatosis progression in CKD.This work was supported by the intramural program of the IRBLleida, the Instituto de Salud Carlos III (RETIC RD16/0009/0011, FIS PI16/01354) and FEDER funds. The authors would like to thank the NEFRONA team (Eva Castro, Virtudes María, Teresa Molí, Teresa Vidal, Meritxell Soria) and the Biobank of RedInRen for their invaluable support. The NEFRONA study investigator group is listed in the supplementary material.American Society of Nephrology2018201820182018info:eu-repo/semantics/articleinfo:eu-repo/semantics/acceptedVersionapplication/pdfhttps://doi.org/10.2215/CJN.07980717http://hdl.handle.net/10459.1/63140http://hdl.handle.net/10459.1/63140reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésVersió postprint del document publicat a: https://doi.org/10.2215/CJN.07980717Clinical Journal of The American Society of Nephrology, 2018, vol. 13, núm. 4, p. 577-584(c) American Society of Nephrology, 2018info:eu-repo/semantics/openAccessoai:recercat.cat:10459.1/631402026-05-29T05:05:01Z
dc.title.none.fl_str_mv Association of FGF-2 Concentrations with Atheroma Progression in Chronic Kidney Disease Patients
Subclinical Atheromatosis progression and FGF-2 in CKD
title Association of FGF-2 Concentrations with Atheroma Progression in Chronic Kidney Disease Patients
spellingShingle Association of FGF-2 Concentrations with Atheroma Progression in Chronic Kidney Disease Patients
Bozic, Milica
Atherosclerosis
Cardiovascular disease
Plaque, Atherosclerotic
title_short Association of FGF-2 Concentrations with Atheroma Progression in Chronic Kidney Disease Patients
title_full Association of FGF-2 Concentrations with Atheroma Progression in Chronic Kidney Disease Patients
title_fullStr Association of FGF-2 Concentrations with Atheroma Progression in Chronic Kidney Disease Patients
title_full_unstemmed Association of FGF-2 Concentrations with Atheroma Progression in Chronic Kidney Disease Patients
title_sort Association of FGF-2 Concentrations with Atheroma Progression in Chronic Kidney Disease Patients
dc.creator.none.fl_str_mv Bozic, Milica
Betriu i Bars, M. Àngels
Bermúdez López, Marcelino
Ortiz, Alberto
Fernández i Giráldez, Elvira
Valdivielso Revilla, José Manuel
author Bozic, Milica
author_facet Bozic, Milica
Betriu i Bars, M. Àngels
Bermúdez López, Marcelino
Ortiz, Alberto
Fernández i Giráldez, Elvira
Valdivielso Revilla, José Manuel
author_role author
author2 Betriu i Bars, M. Àngels
Bermúdez López, Marcelino
Ortiz, Alberto
Fernández i Giráldez, Elvira
Valdivielso Revilla, José Manuel
author2_role author
author
author
author
author
dc.subject.none.fl_str_mv Atherosclerosis
Cardiovascular disease
Plaque, Atherosclerotic
topic Atherosclerosis
Cardiovascular disease
Plaque, Atherosclerotic
description Background and objectives: Atherosclerosis is highly prevalent in CKD. The rate of progression of atherosclerosis is associated with cardiovascular events. Fibroblast growth factor 2 (FGF-2) is a member of the FGF family with potentially both protective and deleterious effects in the development of atherosclerosis. The role of circulating FGF-2 levels in the progression of atherosclerosis in CKD is unknown. Design, setting, participants, & measurements: We used a multicenter, prospective, observational cohorts study of 481 patients with CKD. We determined the presence of atheroma plaque in ten arterial territories by carotid and femoral ultrasounds. Progression of atheromatosis was defined as an increase in the number of territories with plaque after 24 months. Plasma levels of FGF-2 were measured by multiplex analysis. A multivariable logistic regression analysis was performed to determine whether plasma FGF-2 levels were associated with atheromatosis progression. Results: Average age of the population was 61 years. The percentage of patients in each CKD stage was 51% in stage 3, 41% in stages 4–5, and 8% in dialysis. A total of 335 patients (70%) showed plaque at baseline. Atheromatosis progressed in 289 patients (67%). FGF-2 levels were similar between patients with or without plaque at baseline (79 versus 88 pg/ml), but lower in patients with atheromatosis progression after 2 years (78 versus 98 pg/ml; P<0.01). In adjusted analyses, higher plasma FGF-2 was associated with lower risk of atheromatosis progression (odds ratio [OR], 0.86; 95% confidence interval [95% CI], 0.76 to 0.96; per 50 pg/ml increment). Analysis of FGF-2 in tertiles showed that atheroma progression was observed for 102 participants in the lowest tertile of FGF-2 (reference group), 86 participants in the middle tertile of FGF-2 (adjusted OR, 0.70; 95% CI, 0.40 to 1.20), and 74 participants in the lowest tertile of FGF-2 (adjusted OR, 0.48; 95% CI, 0.28 to 0.82). Conclusions: Low FGF-2 levels are independently associated with atheromatosis progression in CKD.
publishDate 2018
dc.date.none.fl_str_mv 2018
2018
2018
2018
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/acceptedVersion
format article
status_str acceptedVersion
dc.identifier.none.fl_str_mv https://doi.org/10.2215/CJN.07980717
http://hdl.handle.net/10459.1/63140
http://hdl.handle.net/10459.1/63140
url https://doi.org/10.2215/CJN.07980717
http://hdl.handle.net/10459.1/63140
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Versió postprint del document publicat a: https://doi.org/10.2215/CJN.07980717
Clinical Journal of The American Society of Nephrology, 2018, vol. 13, núm. 4, p. 577-584
dc.rights.none.fl_str_mv (c) American Society of Nephrology, 2018
info:eu-repo/semantics/openAccess
rights_invalid_str_mv (c) American Society of Nephrology, 2018
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv American Society of Nephrology
publisher.none.fl_str_mv American Society of Nephrology
dc.source.none.fl_str_mv reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869413191227801600
score 15.811543

Similares en LA Referencia